Skip to main content
Figure 4 | Virology Journal

Figure 4

From: Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against Influenza A M2 protein

Figure 4

Dose response and therapeutic activity of scFv-msFc-γ2c D005. (A) Dose titration. Mice were treated with the indicated amounts of antibody on day -2, infected with Influenza A virus PR8 on day 0, and survival was monitored for 21 days. (B) Therapeutic setting. Mice were infected with Influenza A virus PR8 on day 0, treated with 200 μg of the antibody on the indicated days, and survival was monitored for 21 days. Control, 200 μg mouse IgG on day -2.

Back to article page

Virology Journal

ISSN: 1743-422X